Very-high-dose phenobarbital for childhood refractory status epilepticus

Area of Science:

• Pediatric Neurology
• Neuropharmacology
• Infectious Diseases

Background:

• Refractory status epilepticus (RSE) poses a significant management challenge in pediatric patients.
• Viral encephalitis is a potential underlying cause of RSE, presenting with diverse neurological symptoms.
• Conventional anti-epileptic drug regimens often fail in managing RSE, necessitating alternative therapeutic strategies.

Observation:

• Three pediatric patients (7-9 years old) presented with RSE, initially characterized by generalized tonic-clonic seizures.
• Seizure manifestations evolved to subtle eye staring, limb/mouth twitching, tachycardia, and pupillary dilation.
• Standard intravenous treatments including phenobarbital, phenytoin, and midazolam infusion were ineffective.

Findings:

• Administration of very-high-dose phenobarbital (up to 80 mg/kg/day) achieved seizure control.
• Achieved serum phenobarbital levels exceeded 1000 mumol/L.
• This high-dose regimen demonstrated a favorable safety profile with milder adverse effects compared to thiopental infusion.

Implications:

• Very-high-dose phenobarbital represents a viable and potentially safer alternative for managing pediatric RSE unresponsive to standard treatments.
• This approach may offer a critical therapeutic option for RSE secondary to viral encephalitis.
• Further research into optimal dosing and long-term outcomes of high-dose phenobarbital in pediatric RSE is warranted.